| Literature DB >> 21466774 |
Serge Bismuth1, Eng Laing Leng, Stéphane Oustric, Jean-Louis Montastruc, Maryse Lapeyre-Mestre.
Abstract
Following the announcement of the future withdrawal in Europe of drugs containing dextropropoxyphene-paracetamol (DXP-P), we performed a postal survey in a randomly selected sample of 350 general practitioners (GP) from the Midi-Pyrénées area (2.6 million inhabitants) in order to investigate which drug (s) they are willing to prescribe in anticipation of the announced withdrawal. Most of GP prescribed DXP-P in acute and chronic pain. In acute pain, GP would switch to codeine-paracetamol (59.1%) or tramadol alone or associated with paracetamol (79%), whereas they would switch to high dose paracetamol (54.7%) and tramadol alone or associated with paracetamol (74.6%) in chronic pain. Switching to other level 2 analgesic drugs after the withdrawal of dextropropoxyphene should be closely monitored because the safety profile of other drugs.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21466774 DOI: 10.2515/therapie/2011004
Source DB: PubMed Journal: Therapie ISSN: 0040-5957 Impact factor: 2.070